REIMBURSEMENT UNRAVELLED: Why blood glucose monitoring products are reimbursement anomalies
This article was originally published in Clinica
In the fifth instalment of Clinica’s new reimbursement series, Dr Mark Charny explains that careful and detailed consideration of the reimbursement, prescribing and purchasing regulations in each market is required to develop a coherent marketing strategy for blood glucose meters and test strips in Europe. He focuses here primarily on the UK, German, French and Italian markets with a glance too at Spain and Sweden
You may also be interested in...
In the final part of Clinica’s series on heath technology assessment in the EU, Mark Charny looks beyond HTA and discusses what factors to consider when gauging the reimbursement potential of your product from a payer’s perspective
In the second part of Clinica’s new series on health technology assessment in the EU, Mark Charny discusses how medtech companies can plan their HTA strategy on a country-specific level and on a broader EU level
Mark Charny provides an update on the key initiatives that have been rolled out in the EU to support cross-border collaboration on health technology assessment for medical devices.